Latest News about Phase 2 Trial
Recent news which mentions Phase 2 Trial
Freeline Therapeutics Touts Encouraging Data From Fabry Disease Program
November 10, 2021
Tickers
FRLN
From Benzinga
Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study
November 10, 2021
Tickers
FNCH
From Benzinga
GeoVax Labs In-Licenses Development Rights To Multi-Antigenic COVID-19 Vaccine Candidate
November 10, 2021
From Benzinga
Seelos Therapeutics To Test Trehalose In Patients With Rare Movement Control Disorder
November 08, 2021
Tickers
SEEL
From Benzinga
From Benzinga
Why Did Calithera Shares Dropped To 52-Week Low In Premarket Friday?
November 05, 2021
Tickers
CALA
From Benzinga
Achieve Life Sciences To Start Cytisinicline's Trial For Nicotine E-cigarette Cessation
November 02, 2021
Tickers
ACHV
From Benzinga
Aldeyra's Dry Eye Disease Trial Meets Primary Endpoint, But Did Not Reach Statistical Significance
November 02, 2021
Tickers
ALDX
From Benzinga
Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting
November 02, 2021
From Benzinga
From Benzinga
From Benzinga
ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged
October 29, 2021
Tickers
ABIO
From Benzinga
From Benzinga
4D Molecular's Fabry Disease Candidate Shows Early Proof-Of-Concept
October 26, 2021
Tickers
FDMT
From Benzinga
Ventyx Jumps Over 20% Today After NASDAQ Debut
October 21, 2021
From Benzinga
PDS Biotech Pauses Recruitment In PDS0101 Combo Cancer Trial
October 21, 2021
From Benzinga
Edesa Biotech Shares Gain As Its COVID-19 Antibody Shows Favorable Mortality Reductions
October 19, 2021
Tickers
EDSA
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.